New Bispecific Antibody for Relapsed Multiple Myeloma Gets Approval
On March 5, 2026, the FDA approved a new combination therapy pairing the bispecific antibody teclistamab (Tecvayli) with daratumumab for adults with...
Category caregivers
New Small Molecule Drug for Psoriatic Arthritis Approved After Trials
The U.S. Food and Drug Administration approved Sotyktu (deucravacitinib) on March 6, 2026, for the treatment of adults with active psoriatic arthritis,...
New Drug Approved for Complement-Mediated Kidney Disease
The FDA has approved several new drugs targeting complement-mediated kidney diseases, marking what experts have called a "landmark year" for nephrology...
New Prescription Approved for Once-Weekly Insulin — No Daily Shots
A once-weekly insulin injection called Awiqli, manufactured by Novo Nordisk, has been approved in more than a dozen countries and could soon reach the...
New Oral Agent for Paroxysmal Nocturnal Hemoglobinuria Approved
The FDA has now approved two oral agents for paroxysmal nocturnal hemoglobinuria, a rare and life-threatening blood disorder that destroys red blood cells...
New CAR-T Cell Therapy Approved for Follicular Lymphoma
The FDA has now approved three CAR-T cell therapies for follicular lymphoma, with the most recent being Breyanzi (lisocabtagene maraleucel), which...
This Blood Pressure Drug Is Now Approved for a Rare Kidney Condition
In April 2025, the FDA granted accelerated approval to Vanrafia (atrasentan), a blood pressure drug now cleared to treat IgA nephropathy, a rare kidney...
New Severe Asthma Biologic Approved for 12-Year-Olds
The FDA approved Exdensur (depemokimab-ulaa) on December 16, 2025, making it the first ultra-long-acting biologic available for severe eosinophilic asthma...
New Drug for Moderate-to-Severe Plaque Psoriasis Approved in Record Time
The FDA today approved ICOTYDE (icotrokinra), the first oral pill that targets the IL-23 pathway for moderate-to-severe plaque psoriasis, marking a...
This Intranasal Drug Is Changing How Seizures Are Treated at Home
Two FDA-approved intranasal sprays — Nayzilam (midazolam) and Valtoco (diazepam) — are fundamentally changing how seizure clusters are managed outside of...